Last edition
News about "Non-Small Cell Lung Cancer "
Genprex has partnered with Roche Diagnostics to validate TROP2 biomarkers for patient selection in non-small cell lung cancer trials, aiming to accelerate precision medicine and improve treatment outcomes.
Non-Small Cell Lung Cancer | 04/08/2026 | By News Bureau
Akeso Doses First Patient in Phase 1b/2 Trial of HER3 ADC for Advanced Lung Cancer
Akeso has dosed the first patient in its Phase 1b/2 AK138D1-201 trial, assessing the HER3-targeted antibody-drug conjugate AK138D1 as monotherapy and in combination with ivonescimab for patients with advanced non-small cell lung cancer.
Non-Small Cell Lung Cancer | 30/07/2026 | By News Bureau | 124
China Grants Priority Review to Leads Biolabs' Opamtistomig for Advanced Neuroendocrine Carcinoma
NMPA accepts biologics license application under expedited review pathway for investigational PD-L1/4-1BB bispecific antibody targeting advanced extrapulmonary neuroendocrine carcinoma after multiple prior therapies.
Non-Small Cell Lung Cancer | 13/07/2026 | By News Bureau | 108
Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial
Roche's investigational KRAS G12C inhibitor divarasib demonstrated superior progression-free and overall survival over approved first-generation therapies in the Phase III Krascendo 1 trial, marking a significant advance in the treatment of previously treated KRAS G12C-mutated non-small cell lung cancer.
Non-Small Cell Lung Cancer | 04/07/2026 | By News Bureau | 238
Nuvation Bio's Taletrectinib Advances UK Regulatory Review for ROS1-Positive Lung Cancer
The UK's MHRA has validated the marketing application for Nuvation Bio's taletrectinib, bringing the next-generation ROS1 inhibitor one step closer to approval for patients with advanced ROS1-positive non-small cell lung cancer in the UK.
Non-Small Cell Lung Cancer | 01/07/2026 | By News Bureau
HARNESS-1 study evaluates RC220 with osimertinib to address treatment resistance in EGFR-mutant non-small cell lung cancer, with the first patient showing no adverse events after initial dosing.
Non-Small Cell Lung Cancer | 26/06/2026 | By News Bureau | 105
Boehringer Ingelheim has initiated 3 phase 3 oncology trials, including DAREON-Lung-1 and DAREON-NEC-1, to evaluate obrixtamig as a DLL3 biomarker-guided treatment approach for hard-to-treat cancers.
Non-Small Cell Lung Cancer | 23/06/2026 | By News Bureau | 206
Leica Biosystems, AstraZeneca and Daiichi Sankyo have expanded their strategic collaboration to develop an AI-enabled immunohistochemistry assay and computational pathology solution for evaluating the TROP2 Normalised Membrane Ratio biomarker in NSCLC, aiming to advance biomarker-driven cancer research and future precision medicine approaches.<br />
Non-Small Cell Lung Cancer | 01/06/2026 | By News Bureau | 163
Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954
Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.
Non-small Cell Lung Cancer | 12/05/2026 | By News Bureau | 293
Samsung Bioepis achieves positive Phase 1 results for Keytruda biosimilar candidate SB27
The biopharmaceutical company announced that its proposed pembrolizumab biosimilar, SB27, met primary pharmacokinetic endpoints in a global Phase 1 study involving non-small cell lung cancer patients, advancing its oncology biosimilar pipeline.
Non-small Cell Lung Cancer | 08/05/2026 | By News Bureau | 215
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy